Evaluate high-risk patient populations for PNH.
Early diagnosis drives effective PNH management
Diverse PNH symptomatology may complicate and delay diagnosis. Disease progression
resulting from serious clinical sequelae reinforces the importance of early diagnosis.
Accordingly, the current availability of an effective PNH treatment option warrants
testing appropriate patients. Click below to learn more about the PNH Diagnostic
Pathway.
New Clinical Cytometry Society guidelines
Now you can more accurately identify and monitor PNH in your practice. Click here
to download the full guidelines.
Do you have high-risk patients in your practice?
Hear how a physician from a large network practice implemented the PNH Diagnostic
Pathway. Click here
References: 1.Parker C, Omine M, Richards S, et al; for International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709. 2. Sugimori C, Chuhjo T, Feng X, et al. Minor population
of CD55-CD59- blood cells predicts response to immunosuppressive
therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308-1314.